Physician profile
Rene E Torres
NPI 1811155534
$5,117.69
in general payments reported to CMS, 2019-2025
33 companies · $862 in 2025
The $862 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $662 · 2023: $1,432 · 2024: $1,260 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,335.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,061.62 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $457.25 | 2021-2024 | |
| Dexcom, INC. | $259.33 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $225.78 | 2021-2025 | Otezla, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $214.13 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $169.33 | 2021-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $139.20 | 2022-2023 | |
| Corcept Therapeutics | $129.34 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.52 | 2021-2025 | Jardiance |
| Pfizer INC. | $107.64 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $105.74 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $86.46 | 2023-2024 | |
| Phadia US INC. | $65.09 | 2021-2024 | Immunocap |
| Glaxosmithkline, LLC. | $65.03 | 2022-2025 | Shingrix, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58.10 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.09 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $53.50 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $52.05 | 2021-2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $48.45 | 2022-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $48.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $40.73 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $36.99 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $26.04 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.39 | 2022 | |
| Lundbeck LLC | $20.52 | 2024 | Rexulti |
| Optinose US, INC. | $18.77 | 2024 | |
| Antares Pharma, INC. | $16.69 | 2024 | Xyosted |
| Astellas Pharma US INC | $15.61 | 2024 | Veozah |
| Genentech USA, INC. | $14.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.